: Primary open angle glaucoma (POAG) is a worldwide disease with IOP being an important risk factor for the disease. Pharmacological and surgical treatments have been mainly targeted on lowering IOP by decreasing aqueous humor production or increasing aqueous humor outflow. Stem cell therapies may open new frontiers in regenerative ophthalmology branch. In POAG there is a strong association with pathologic degeneration of the trabecular meshwork (TM) and regenerative cell-therapy approaches have been focused mainly on modulation of the degeneration. Many different adult stem cell types have been discovered in different parts of the eye such as the corneal endothelium (CE) and anterior non-filtering portion of the TM called Schwalbe’s ring region. These stem cells may supply new cells for the TM and may regenerate the TM structure thus reducing IOP and restore the homeostatic function of the eye. In this paper, we report the studies’ latest findings and present our perspective on approaches that seem promising in the management of POAG.
{"title":"Regeneration of trabecular meshwork in primary open angle glaucoma by stem cell therapy: a new treatment approach","authors":"E. Vingolo, A. Chabib, F. Anselmucci","doi":"10.2147/TRRM.S160229","DOIUrl":"https://doi.org/10.2147/TRRM.S160229","url":null,"abstract":": Primary open angle glaucoma (POAG) is a worldwide disease with IOP being an important risk factor for the disease. Pharmacological and surgical treatments have been mainly targeted on lowering IOP by decreasing aqueous humor production or increasing aqueous humor outflow. Stem cell therapies may open new frontiers in regenerative ophthalmology branch. In POAG there is a strong association with pathologic degeneration of the trabecular meshwork (TM) and regenerative cell-therapy approaches have been focused mainly on modulation of the degeneration. Many different adult stem cell types have been discovered in different parts of the eye such as the corneal endothelium (CE) and anterior non-filtering portion of the TM called Schwalbe’s ring region. These stem cells may supply new cells for the TM and may regenerate the TM structure thus reducing IOP and restore the homeostatic function of the eye. In this paper, we report the studies’ latest findings and present our perspective on approaches that seem promising in the management of POAG.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"1 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S160229","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68494685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hannah Rahim, Michael R. Taylor, S. Hirota, S. Greenway
: Improved long-term survival following solid-organ transplantation (SOT) has remained elusive over the past several decades, despite significant advances in early survival. The microbiome refers to the genetic material belonging to microbes that live in an ecological balance with the human host, and its importance in human health is increasingly recognized. Extensive research pertaining to the human microbiome has demonstrated that compositional changes in the microbiome can contribute to such diseases as inflammatory bowel disease, metabolic syndrome, and (recently) many of the comorbidities that develop after SOT. It is suggested that the microbiome may be an important environmental variable that could influence health outcomes after SOT. Many factors related to SOT, including end-stage organ disease, surgery, and the use of antimicrobial prophylaxis and immunosuppressive drugs, have been shown to affect microbial composition and function negatively. These alterations could compromise health outcomes after SOT through the dysregulation of important host–microbe interactions, including the modulation of local and systemic host immune function by the gut microbiome, and could contribute to morbidity and even allograft rejection. Such interventions as synbiotic therapy and fecal microbiota transplantation have the potential to prevent or reverse disruption of the microbiome related to SOT and thereby improve the longevity of transplant recipients. Although microbiome research is still a relatively new field, progress is accelerating exponentially. Future research on host– microbiome interactions in the context of SOT will facilitate the development of microbiome-directed treatments to improve patient outcomes on pre- and post-SOT.
{"title":"Microbiome alterations following solid-organ transplantation: consequences, solutions, and prevention","authors":"Hannah Rahim, Michael R. Taylor, S. Hirota, S. Greenway","doi":"10.2147/TRRM.S143063","DOIUrl":"https://doi.org/10.2147/TRRM.S143063","url":null,"abstract":": Improved long-term survival following solid-organ transplantation (SOT) has remained elusive over the past several decades, despite significant advances in early survival. The microbiome refers to the genetic material belonging to microbes that live in an ecological balance with the human host, and its importance in human health is increasingly recognized. Extensive research pertaining to the human microbiome has demonstrated that compositional changes in the microbiome can contribute to such diseases as inflammatory bowel disease, metabolic syndrome, and (recently) many of the comorbidities that develop after SOT. It is suggested that the microbiome may be an important environmental variable that could influence health outcomes after SOT. Many factors related to SOT, including end-stage organ disease, surgery, and the use of antimicrobial prophylaxis and immunosuppressive drugs, have been shown to affect microbial composition and function negatively. These alterations could compromise health outcomes after SOT through the dysregulation of important host–microbe interactions, including the modulation of local and systemic host immune function by the gut microbiome, and could contribute to morbidity and even allograft rejection. Such interventions as synbiotic therapy and fecal microbiota transplantation have the potential to prevent or reverse disruption of the microbiome related to SOT and thereby improve the longevity of transplant recipients. Although microbiome research is still a relatively new field, progress is accelerating exponentially. Future research on host– microbiome interactions in the context of SOT will facilitate the development of microbiome-directed treatments to improve patient outcomes on pre- and post-SOT.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"10 1","pages":"1-11"},"PeriodicalIF":0.9,"publicationDate":"2018-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S143063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45332348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 49–56 Transplant Research and Risk Management Dovepress
{"title":"One-year survival rate of renal transplant: factors influencing the outcome","authors":"S. Rezapour, A. Yarmohammadi, M. Tavakkoli","doi":"10.2147/TRRM.S150080","DOIUrl":"https://doi.org/10.2147/TRRM.S150080","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 49–56 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"49-56"},"PeriodicalIF":0.9,"publicationDate":"2017-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S150080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45985248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Tsujimura, M. Ota, K. Chinen, Kiyomi Nagayama, M. Oroku, Morikuni Nishihira, Y. Shiohira, K. Iseki, H. Ishida, K. Tanabe
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 43–48 Transplant Research and Risk Management Dovepress
{"title":"Efficacy of everolimus in ABO-incompatible kidney transplantation: a retrospective study","authors":"K. Tsujimura, M. Ota, K. Chinen, Kiyomi Nagayama, M. Oroku, Morikuni Nishihira, Y. Shiohira, K. Iseki, H. Ishida, K. Tanabe","doi":"10.2147/TRRM.S137727","DOIUrl":"https://doi.org/10.2147/TRRM.S137727","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 43–48 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"43-48"},"PeriodicalIF":0.9,"publicationDate":"2017-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S137727","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42191385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 39–41 Transplant Research and Risk Management Dovepress
{"title":"Response to “Hand transplantation: current challenges and future prospects”","authors":"J. Trofe‐Clark, L. Levin","doi":"10.2147/TRRM.S140390","DOIUrl":"https://doi.org/10.2147/TRRM.S140390","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 39–41 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"39-41"},"PeriodicalIF":0.9,"publicationDate":"2017-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S140390","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44506090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Epstein, Melissa M. Parker, A. Lucero, R. Chaudhary, Eyun Song, D. Weisshaar
Objective: The purpose of this study was to evaluate the effects of depression and anxiety before heart transplant on all-cause mortality after heart transplant in a Northern California cohort. Methods: A total of 130 adult patients with heart transplants enrolled at Kaiser Permanente between June 2005 and December 2013 were included in a retrospective chart review. Preoperative depression and anxiety, evidenced by diagnoses, and other risk factors for all-cause mortality were investigated. Statistical methods included Kaplan–Meier survival analysis and Cox proportional hazard regression models. Results: After risk adjustment, patients with preoperative depression and anxiety diagnoses had higher risk of all-cause mortality at 2 years (hazard ratio [HR] = 4.2, 95% confidence interval [CI]: 1.1, 15.0, p = 0.03) and 3 years (HR = 3.7, 95% CI: 1.2, 11.9, p = 0.04) following heart transplant than those without depression or anxiety. This finding did not reach statistical significance at 5 years post-heart transplant (HR = 2.0, 95% CI: 0.8, 5.3, p = 0.14). Conclusion: The findings suggest an association between preoperative depression and anxiety with mortality in heart transplant patients 2 and 3 years post-transplant.
{"title":"Association of depression and anxiety before heart transplant with mortality after transplant: a single-center experience","authors":"F. Epstein, Melissa M. Parker, A. Lucero, R. Chaudhary, Eyun Song, D. Weisshaar","doi":"10.2147/TRRM.S132400","DOIUrl":"https://doi.org/10.2147/TRRM.S132400","url":null,"abstract":"Objective: The purpose of this study was to evaluate the effects of depression and anxiety before heart transplant on all-cause mortality after heart transplant in a Northern California cohort. Methods: A total of 130 adult patients with heart transplants enrolled at Kaiser Permanente between June 2005 and December 2013 were included in a retrospective chart review. Preoperative depression and anxiety, evidenced by diagnoses, and other risk factors for all-cause mortality were investigated. Statistical methods included Kaplan–Meier survival analysis and Cox proportional hazard regression models. Results: After risk adjustment, patients with preoperative depression and anxiety diagnoses had higher risk of all-cause mortality at 2 years (hazard ratio [HR] = 4.2, 95% confidence interval [CI]: 1.1, 15.0, p = 0.03) and 3 years (HR = 3.7, 95% CI: 1.2, 11.9, p = 0.04) following heart transplant than those without depression or anxiety. This finding did not reach statistical significance at 5 years post-heart transplant (HR = 2.0, 95% CI: 0.8, 5.3, p = 0.14). Conclusion: The findings suggest an association between preoperative depression and anxiety with mortality in heart transplant patients 2 and 3 years post-transplant.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"31-38"},"PeriodicalIF":0.9,"publicationDate":"2017-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S132400","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48602881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 23–29 Transplant Research and Risk Management Dovepress
{"title":"Hand transplantation: current challenges and future prospects","authors":"Noor Alolabi, Haley F. M. Augustine, A.M.T. ThomÃ","doi":"10.2147/TRRM.S94298","DOIUrl":"https://doi.org/10.2147/TRRM.S94298","url":null,"abstract":"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Transplant Research and Risk Management 2017:9 23–29 Transplant Research and Risk Management Dovepress","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"23-29"},"PeriodicalIF":0.9,"publicationDate":"2017-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S94298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42210821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: Posttransplant lymphoproliferative disease (PTLD) is a major complication after solid organ transplantation and allogeneic hematopoietic stem cell transplantation. The spectrum of PTLD ranges from benign hyperplasia to malignant lymphoma, representing one of the most relevant malignancies in these patients. Most PTLDs are driven by latent Epstein–Barr virus infections. The backbone of treatment is reduction of immunosuppression. Further treatment depends on the type of PTLD and the type of transplantation. A multidisciplinary approach involving transplant team, hematologists, and other disciplines is crucial for the diagnosis and treatment of PTLD and for concurrent preservation of the transplant function. In this study, known pathomechanisms, risk preemptive and especially emerging treatment algorithms in PTLD were reviewed.
{"title":"Risk factors, diagnosis, and management of posttransplant lymphoproliferative disorder: improving patient outcomes with a multidisciplinary treatment approach","authors":"K. Ligeti, L. Müller, C. Müller-Tidow, T. Weber","doi":"10.2147/TRRM.S84744","DOIUrl":"https://doi.org/10.2147/TRRM.S84744","url":null,"abstract":": Posttransplant lymphoproliferative disease (PTLD) is a major complication after solid organ transplantation and allogeneic hematopoietic stem cell transplantation. The spectrum of PTLD ranges from benign hyperplasia to malignant lymphoma, representing one of the most relevant malignancies in these patients. Most PTLDs are driven by latent Epstein–Barr virus infections. The backbone of treatment is reduction of immunosuppression. Further treatment depends on the type of PTLD and the type of transplantation. A multidisciplinary approach involving transplant team, hematologists, and other disciplines is crucial for the diagnosis and treatment of PTLD and for concurrent preservation of the transplant function. In this study, known pathomechanisms, risk preemptive and especially emerging treatment algorithms in PTLD were reviewed.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"1-14"},"PeriodicalIF":0.9,"publicationDate":"2017-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S84744","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46045196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Capelli, O. Baraldi, G. Comai, E. Sala, M. Cappuccilli, C. Donadei, V. Cuna, M. Angelini, G. Donati, G. Manna
Background: Acute kidney injury occurring after kidney transplantation frequently leads to delayed graft function with detrimental long-term effects on graft survival. Neutrophil gelati-nase-associated lipocalin (NGAL) has been validated as a biomarker for posttransplant acute kidney injury. This observational study aimed to assess the effectiveness of urinary NGAL as a predictive marker of delayed graft function. Materials and methods: Forty-three consecutive patients who received renal transplant were included in the study. Urine samples were collected before transplant (if available) and at days 1, 3, 7, 14, and 30 after transplant, and urinary NGAL levels were quantified by enzyme-linked immunosorbent assay. Results: Urinary NGAL progressively decreased after transplant in patients with both delayed and immediate graft function. However, urinary NGAL concentration remained significantly higher in the presence of delayed graft function in the first 14 days after transplant. The area under the receiver operating characteristic curve showed that the ability of urinary NGAL to predict delayed graft function was accurate at 1st and 3rd days after transplant. Conclusion: The relative decrease of urinary NGAL concentration rather than its absolute value may be relevant to predict delayed graft function after renal transplant. In particular, urinary NGAL area under the curve for 3 days seems to be a more valuable parameter of decision making in the early posttransplant period.
{"title":"Urinary neutrophil gelatinase-associated lipocalin is a biomarker of delayed graft function after kidney transplantation","authors":"I. Capelli, O. Baraldi, G. Comai, E. Sala, M. Cappuccilli, C. Donadei, V. Cuna, M. Angelini, G. Donati, G. Manna","doi":"10.2147/TRRM.S122090","DOIUrl":"https://doi.org/10.2147/TRRM.S122090","url":null,"abstract":"Background: Acute kidney injury occurring after kidney transplantation frequently leads to delayed graft function with detrimental long-term effects on graft survival. Neutrophil gelati-nase-associated lipocalin (NGAL) has been validated as a biomarker for posttransplant acute kidney injury. This observational study aimed to assess the effectiveness of urinary NGAL as a predictive marker of delayed graft function. Materials and methods: Forty-three consecutive patients who received renal transplant were included in the study. Urine samples were collected before transplant (if available) and at days 1, 3, 7, 14, and 30 after transplant, and urinary NGAL levels were quantified by enzyme-linked immunosorbent assay. Results: Urinary NGAL progressively decreased after transplant in patients with both delayed and immediate graft function. However, urinary NGAL concentration remained significantly higher in the presence of delayed graft function in the first 14 days after transplant. The area under the receiver operating characteristic curve showed that the ability of urinary NGAL to predict delayed graft function was accurate at 1st and 3rd days after transplant. Conclusion: The relative decrease of urinary NGAL concentration rather than its absolute value may be relevant to predict delayed graft function after renal transplant. In particular, urinary NGAL area under the curve for 3 days seems to be a more valuable parameter of decision making in the early posttransplant period.","PeriodicalId":41597,"journal":{"name":"Transplant Research and Risk Management","volume":"9 1","pages":"15-21"},"PeriodicalIF":0.9,"publicationDate":"2017-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/TRRM.S122090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68494519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：